Core Viewpoint - Zhejiang Huahai Pharmaceutical Co., Ltd. has received approval from the National Medical Products Administration for the clinical trial of its drug HB0043, which targets pyogenic hidradenitis [1][2]. Drug Basic Information - Drug Name: Injectable HB0043 - Indication: Pyogenic Hidradenitis - Dosage Form: Injectable Sterile Powder - Application: Clinical Trial - Applicants: Shanghai Huatai Biopharmaceutical Co., Ltd. and Huabo Biopharmaceutical Technology (Shanghai) Co., Ltd. [1] Additional Drug Information - In May 2025, Huatai received approval from New Zealand's Medicines and Medical Devices Safety Authority to conduct Phase I clinical trials for HB0043 in New Zealand [1]. - The total R&D investment in the project has reached approximately RMB 69.09 million [3]. Drug Mechanism and Advantages - HB0043 is a recombinant humanized IgG1 bispecific antibody that targets both IL-17A and IL-36R, demonstrating high binding and blocking activity [3]. - Compared to monoclonal antibodies, HB0043 shows stronger efficacy in inhibiting cytokine-induced inflammation and fibrosis through dual blockade of IL-17A and IL-36R [3]. - It has proven superior efficacy in various animal disease models, including atopic dermatitis, idiopathic pulmonary fibrosis, diabetic nephropathy, and neutrophilic asthma [3]. - HB0043 is the first bispecific drug targeting IL-17A and IL-36R globally, potentially overcoming the limitations of existing single-target therapies [4].

Macro News - The State Council, led by Premier Li Qiang, emphasized the need to implement the "Artificial Intelligence +" initiative to promote large-scale commercial applications of AI [3] - The National Development and Reform Commission highlighted the importance of advancing the national unified market and reducing "involution" competition [3] Industry News - Nvidia's H20 computing chip has been reported to have serious security issues, leading to a meeting with the National Internet Information Office to discuss the risks associated with its sale to China [6] - The National Health Commission and the National Administration of Traditional Chinese Medicine released the 2025 version of the treatment plan for Chikungunya fever, which is transmitted by mosquitoes [6] - The Industrial and Commercial Bank of China has made combating "involution" competition a key focus for the second half of the year [6] - In the textile industry, from January to June, the industrial added value of large-scale textile enterprises grew by 3.1%, while total revenue decreased by 3.0% [6] - The domestic gaming market achieved actual sales revenue of 168 billion yuan in the first half of 2025, marking a year-on-year growth of 14.08% [6] - Major steel companies in China have initiated a "counter-speculation" action, suspending molybdenum iron purchases to address irrational price increases [6] - The National Medical Insurance Administration has developed a pricing mechanism for newly launched drugs, including costs related to brain-computer interface technologies [8] Company News - Daodaoquan announced a 563% year-on-year increase in net profit for the first half of the year, proposing a dividend of 1.76 yuan per share [10] - Xizang Tourism stated that it would apply for a trading suspension if significant abnormal trading continues [11] - Ding Tong Technology announced that its controlling shareholder plans to transfer 3% of the company's shares [12] - Ankai Micro announced the launch of the AK1037 series low-power lock control SoC chip [13] - Heng Rui Pharmaceutical received approval for clinical trials of its HRS-5041 tablet [14] - China Petroleum & Chemical Corporation (Sinopec) expects a net profit of 20.1 billion to 21.6 billion yuan for the first half of the year [17] Global Market - The three major US stock indices closed lower, with the Dow Jones down 0.74% and the Nasdaq down 0.03% [22] - WTI crude oil futures fell by 1.06% to $69.26 per barrel, while Brent crude oil futures dropped by 0.97% to $72.53 per barrel [22] - Apple's third-quarter revenue reached $94.04 billion, a year-on-year increase of 9.6% [22] Investment Opportunities - The smart elderly care robot industry is experiencing a surge in technological integration and application, with the market expected to reach 50 billion yuan by 2025 [24] - The 2025 Asia-Pacific Biopharmaceutical Cooperation Summit will focus on global collaborative innovation, with a sustainable outlook for the innovative drug sector [25] - AI glasses are anticipated to become a significant medium for AI applications, with global sales expected to reach 3.5 million units by 2025, a 230% year-on-year increase [26] - The demand for thermal management solutions is increasing due to the performance requirements brought by AI advancements [27][28]

Key Points - Tibet Tourism may apply for suspension of trading if significant abnormalities occur in stock transactions [1] - Southern Road Machinery's stock price has deviated from its fundamental situation [1] - Industrial Fulian's major customers and products have not undergone significant changes [1] - Yingweike has established a relatively complete liquid cooling technology and product solution capability [1] - Victory Energy's operational situation remains normal with no significant changes in the internal and external business environment [1] - Qizheng Tibetan Medicine's operational situation is normal with no significant changes in the internal and external business environment [1] - Dongxin Co. states that its investment in Shanghai Lishuan's chip products is not applicable for large model computing clusters [1] - Guosheng Co. has obtained project filing related to PEEK from its wholly-owned subsidiary [1] - Action Education's actual controller proposed a mid-term dividend of 10 yuan per 10 shares [1] Mergers and Acquisitions - Darui Electronics plans to acquire 80% of Weiste's equity through capital increase and share acquisition [1] - Dashengda intends to acquire 30% equity of Thailand's Far East [1] Financing - Aoshikang plans to issue convertible bonds not exceeding 1 billion yuan for high-end printed circuit board projects [1] - Sixuan New Materials intends to raise no more than 466 million yuan through a private placement [1] - Changhua Chemical plans to raise no more than 230 million yuan for a carbon dioxide polyether project [1] Share Buybacks and Reductions - Fuanna plans to repurchase shares worth between 55.85 million and 104 million yuan [1] - Jiangnan Yifan's board member intends to increase his stake in the company [1] - Jieya Co. and its concerted parties plan to reduce their holdings by no more than 4.95% [1] - Other companies including Tongda Co., Haohan Deep, and Wanhu Chemical also plan to reduce their holdings [1] Operational Data - Sinopec expects a net profit decline of 39.5% to 43.7% year-on-year for the first half of the year [1] - Qingdao Bank reported a net profit of 3.065 billion yuan for the first half, up 16.05% year-on-year [1] - Daodaquan's net profit increased by 563.15% year-on-year, proposing a dividend of 1.76 yuan per 10 shares [1] - Zhengdan Co. reported a net profit increase of 120.35% year-on-year, proposing a dividend of 3 yuan per 10 shares [1] - Other companies reported varying profit changes, including losses and significant increases [1] Contracts and Major Investments - Sanhui Electric signed a framework contract for robot equipment sales [1] - Zhejiang University Network New's subsidiary won a smart engineering project worth 94.2712 million yuan [1] - New Aluminum Times plans to invest no less than 500 million yuan in a project for lightweight, high-strength auto parts [1] - Zhishang Technology will use part of its raised funds for a smart manufacturing production base in Vietnam [1]

Core Viewpoint - Zhejiang Huahai Pharmaceutical Co., Ltd. has received approval from the National Medical Products Administration for clinical trials of its drug HB0043, which targets pyogenic hidradenitis and represents a significant advancement in the treatment of autoimmune diseases [1][2]. Group 1: Drug Information - The drug HB0043 is a recombinant humanized IgG1 bispecific antibody that targets both IL-17A and IL-36R, demonstrating high binding and blocking activity [2]. - HB0043 has shown superior efficacy compared to monoclonal antibodies in various animal disease models, including atopic dermatitis, idiopathic pulmonary fibrosis, diabetic nephropathy, and neutrophilic asthma [2]. - The drug is expected to provide new therapeutic strategies for immune-mediated inflammatory skin diseases and fibrotic diseases, addressing the limitations of single-factor blocking therapies [2][3]. Group 2: Clinical Trial Approval - The drug has received approval for clinical trials, with the first phase set to take place in New Zealand, as approved by the Ethics Committee [1]. - The company has invested approximately RMB 69.09 million in the research and development of HB0043 to date [2]. Group 3: Competitive Advantage - HB0043 is the first bispecific antibody globally targeting both IL-17A and IL-36R, potentially overcoming the limitations of existing single-target therapies [3]. - The drug is positioned to be widely applicable in various Th17/IL-36 related immune-mediated diseases, showcasing a first-in-class advantage in its mechanism and potential [3].

Group 1: Clinical Trials and Approvals - Heng Rui Medicine received clinical trial approval for HRS-5041 tablets for prostate cancer treatment, a novel AR-PROTAC small molecule with potential to overcome resistance compared to second-generation AR inhibitors [1] - Microchip Biotech's CS231295 tablets received FDA approval for a Phase I clinical trial targeting advanced solid tumors, noted for its ability to penetrate the blood-brain barrier [2] - Shuyuan obtained a summary report for BDB-001 injection, showing significant clinical advantages in reducing hormone dosage for ANCA-associated vasculitis, with plans to advance to Phase III trials [5] - Huayi Pharmaceutical's HSK3486 received FDA application acceptance for marketing [12] Group 2: Financial Performance - Daodaoquan reported a 563.15% increase in net profit for the first half of 2025, with revenue of 2.792 billion yuan, driven by improved sales and reduced raw material costs [4] - China Petroleum and Chemical Corporation (Sinopec) expects a net profit of 20.1 billion to 21.6 billion yuan for the first half of 2025, reflecting a decline due to falling oil prices and market competition [6] Group 3: Shareholder Actions - Wanhua Chemical's major shareholder plans to reduce its stake by up to 0.54%, equating to no more than 17 million shares, due to personal financial needs [2] - Ding Tong Technology's controlling shareholder intends to transfer 3% of the company's shares, totaling 417.6 million shares, for similar financial reasons [7] Group 4: New Projects and Investments - Guo En Co., Ltd. announced a project to establish a new platform for PEEK and polystyrene engineering materials with an investment of 960 million yuan, enhancing competitiveness in specialty engineering plastics [8] - Shanying International plans to establish a partnership with a valuation of 2.977 billion yuan to attract long-term investors, including state-owned capital [8]

（文章来源：证券日报） 证券日报网讯 7月31日晚间，华海药业发布公告称，近日，公司的下属子公司上海华奥泰生物药业股份 有限公司和华博生物医药技术（上海）有限公司收到国家药品监督管理局核准签发的注射用HB0043的 《药物临床试验批准通知书》。 ...

Core Viewpoint - The fourth Synthetic Biology and Green Bio-Manufacturing Conference (SynBioCon 2025) will be held from August 20-22 in Ningbo, Zhejiang, focusing on the integration of AI with bio-manufacturing, green chemistry, new materials, future food, and agriculture [1]. Group 1: Conference Overview - The conference aims to explore the development trends of the bio-manufacturing industry during the 14th Five-Year Plan, innovations driven by AI, and the technologies that will sustain the vitality of the bio-manufacturing sector [1]. - Various activities will be held concurrently, including a Youth Forum on Bio-Manufacturing, a high-level roundtable discussion, a closed-door seminar on the "2025 AI Empowering Bio-Manufacturing Industry Innovation Development Blue Book," and a showcase of synthetic biology achievements [1]. Group 2: Organizing Institutions - The conference is organized by Ningbo Detaizhong Research Information Technology Co., Ltd. (DT New Materials) and co-organized by several institutions, including Peking University Ningbo Institute of Ocean Medicine and Ningbo Enzyme Science Bioengineering Co., Ltd. [2]. - Supporting organizations include the Chinese Society of Biotechnology's Biobased Materials Committee, Zhejiang Synthetic Biology Industry Technology Alliance, and various other academic and research institutions [2]. Group 3: Conference Agenda - The agenda includes registration and sign-in on August 20, followed by a high-level roundtable discussion and a Youth Forum [5][9]. - The opening ceremony and macro forum on bio-manufacturing will take place on August 21, along with specialized forums on green chemistry and new materials, and AI's role in bio-manufacturing [6][19]. - The final day will feature discussions on future food and agriculture, along with a showcase of technological achievements in synthetic biology [28][29]. Group 4: Industry Insights - The conference will release the "China Synthetic Biology Industry Distribution Map (2025 Edition)," which includes a list of over 500 representative companies in the bio-manufacturing sector [31]. - The event will also highlight the achievements of various companies and research institutions in the field of bio-manufacturing, showcasing innovations and applications [31][34].

Group 1: Drug Development and Clinical Trials - Heng Rui Medicine received clinical trial approval for HRS-5041, a new AR-PROTAC small molecule for prostate cancer treatment, showing significant degradation of AR proteins and potential to overcome resistance compared to second-generation AR inhibitors [1] - Huahai Pharmaceutical's HB0043, the world's first dual-target antibody for IL-17A and IL-36R, received clinical trial approval, aimed at treating various autoimmune diseases with a development cost of approximately 69.09 million yuan [4] - Microchip Biotech's CS231295, a selective AuroraB inhibitor, received FDA approval for a Phase I clinical trial targeting advanced solid tumors, with no similar drugs currently in clinical trials globally [5] - Shutai Shen's BDB-001 injection for ANCA-associated vasculitis showed significant clinical advantages in hormone reduction during Phase I/II trials, prompting plans for Phase III trials [6] - Yahui Medicine's APL-1401 for moderate to severe active ulcerative colitis showed positive preliminary results in Phase Ib trials, with plans for further evaluation in a larger patient group [8] Group 2: Corporate Actions and Financial Updates - Wanhua Chemical's major shareholder plans to reduce its stake by up to 0.54%, equivalent to 17 million shares, due to personal financial needs, with the reduction period set from August 22, 2025, to November 21, 2025 [2] - Shanying International plans to establish a partnership valued at 2.977 billion yuan to attract long-term investors, enhancing its sustainable development and core competitiveness [3] - Ding Tong Technology's controlling shareholder intends to transfer 3% of the company's shares, amounting to 417,600 shares, for personal financial needs [7] - Aokang plans to issue convertible bonds to raise no more than 1 billion yuan for high-end printed circuit board projects [9] - Ankai Micro launched the AK1037 series low-power lock control SoC chip, enhancing its product matrix in smart lock solutions [10]

| 股票简称：华海药业 | 股票代码：600521 | 公告编号：临 | 号 | 2025-086 | | --- | --- | --- | --- | --- | | 债券简称：华海转债 | 债券代码：110076 | | | | 浙江华海药业股份有限公司 关于下属子公司获得药物临床试验许可的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 近日，浙江华海药业股份有限公司（以下简称"华海药业"或"公司"）的下属 子公司上海华奥泰生物药业股份有限公司（以下简称"华奥泰"）和华博生物医药技 术（上海）有限公司（以下简称"华博生物"）收到国家药品监督管理局（以下简称 "国家药监局"）核准签发的注射用 HB0043 的《药物临床试验批准通知书》。现将相 关情况公告如下： 适应症：化脓性汗腺炎 剂型：注射用无菌粉末 申请事项：临床试验 申请人：上海华奥泰生物药业股份有限公司；华博生物医药技术（上海）有限公 司 结论：同意开展临床试验 二、药物的其他相关情况 2025 年 5 月，公司下属子公司华奥泰获得新西兰药品和医疗器械 ...

Core Insights - Huahai Pharmaceutical's subsidiary, Shanghai Huatai Biopharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the clinical trial of HB0043, a bispecific antibody targeting IL-17A and IL-36R, aimed at treating various autoimmune diseases [1][2] Group 1: Product Development - HB0043 is a recombinant humanized IgG1 bispecific antibody that targets both IL-17A and IL-36R, demonstrating high binding and blocking activity [1] - The drug has shown superior efficacy compared to monoclonal antibodies in various animal disease models, including atopic dermatitis, idiopathic pulmonary fibrosis, diabetic nephropathy, and neutrophilic asthma [1] Group 2: Market Potential - As the first bispecific drug targeting IL-17A and IL-36R globally, HB0043 is expected to overcome the limitations of existing single-target therapies [2] - Current therapies targeting IL-17A and IL-36R have shown positive effects in multiple indications, but there are still shortcomings in addressing inflammation in some patients [2] - HB0043's innovative dual-target approach is anticipated to have broad applications in various Th17/IL-36 related immune-mediated diseases, showcasing a first-in-class advantage [2]